|
|
 |
| |
AAO-HNSF 2010
September 26-29, 2010
Boston, Massachusetts
NACFC 2010
October 21-23, 2010
Baltimore, Maryland |
|
|
|
|
|
|
|
| |
PARI nebulizers are considered the
gold
standard for clinical trials, and recommended in commercial sales
including:
Pulmicort® (AstraZeneca)
Xopenex® (Sepracor)
Perforomist (Dey)
Brovana (Sepracor)
 |
|
| |
|
The future of effective aerosol therapies
lies in the optimization of drug-to-device and
device-to-drug.
PARI Pharma has taken the
next step and combined
formulation development,
next generation aerosol
platforms, and aerosol characterization under
one roof.
We are currently working with both the eFlow® Technology (lower respiratory) and Vibrent Technology (upper respiratory) Advanced Aerosol delivery platforms.
This multifunctional development program is the
key to creating targeted therapies with high
deposition amounts, low side-effect profiles,
improved patient compliance…and better controlled,
healthier patients.
After 100 years, we know aerosol science
and aerosol delivery.
|
|
|
|
|
|
| |
Partner Press Release:
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its head-to-head Phase III clinical trial of Cayston® (aztreonam for inhalation solution) versus tobramycin inhalation solution (TIS) in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (P. aeruginosa) achieved one of its co-primary endpoints of non-inferiority for mean percent change in forced expiratory volume in one second (FEV1) percent predicted after 28 days of treatment. [more]
- - - - - - - - - - - - - - - - Partner Press Release:
Transave, Inc., today reported interim
results from a multi-cycle Phase II open label clinical trial in cystic fibrosis (CF) patients on its lead investigational drug, ARIKACETM (liposomal amikacin for inhalation). [more]
- - - - - - - - - - - - - - - -
Partner Press Release
Transave Inc. today announced that the United States Patent and Trademark Office has issued an important composition of matter patent (U.S. Patent No. 7,718,189) for liposomal aminoglycoside formulations including its lead compound, ARIKACE™ (liposomal amikacin for inhalation). [more]
|
|
| |
|
